MedTrace Logo

Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

NCT05628545 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2023-01-18

No results posted yet for this study

Summary

Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.

The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.

Conditions

Interventions

BIOLOGICAL

GDKM-100 injection

Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.

Sponsors & Collaborators

  • Jinan University Guangzhou

    collaborator OTHER

  • Guangdong GD Kongming Biotech LLC

    lead INDUSTRY

Principal Investigators

  • Zhi nan Yin, PhD.MD. · Jinan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-02-28
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05628545 on ClinicalTrials.gov